Oragenics Inc. short interest in 2022
In 2022, Oragenics Inc.'s disclosed short interest ran from 2.86% of shares outstanding on 14 Jan 2022 to 1.39% on 30 Dec 2022, a change of -1.47 percentage points. The year's high was 2.87% on 15 Feb 2022 and its low 1.14% on 15 Aug 2022, averaging 1.94% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.56 days on 15 Jul 2022. Full history: Oragenics Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 2.86% (14 Jan 2022)
- End of year
- 1.39% (30 Dec 2022)
- Change
- -1.47 pp
- High
- 2.87% (15 Feb 2022)
- Low
- 1.14% (15 Aug 2022)
- Average
- 1.94%
- Highest days to cover
- 10.56 (15 Jul 2022)
- SEC filings marked
- 4
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.86% | 1.05 | |
| 31 Jan 2022 | 2.80% | 3.07 | |
| 15 Feb 2022 | 2.87% | 4.40 | |
| 28 Feb 2022 | 2.08% | 3.31 | |
| 15 Mar 2022 | 2.85% | 3.82 | |
| 31 Mar 2022 | 2.55% | 3.07 | 10-K filed |
| 14 Apr 2022 | 2.64% | 3.04 | |
| 29 Apr 2022 | 2.64% | 6.97 | |
| 13 May 2022 | 1.79% | 3.73 | 10-Q filed |
| 31 May 2022 | 2.40% | 5.93 | |
| 15 Jun 2022 | 2.05% | 6.63 | |
| 30 Jun 2022 | 2.00% | 6.62 | |
| 15 Jul 2022 | 1.80% | 10.56 | |
| 29 Jul 2022 | 1.64% | 7.09 | |
| 15 Aug 2022 | 1.14% | 4.78 | 10-Q filed |
| 31 Aug 2022 | 1.45% | 7.18 | |
| 15 Sep 2022 | 1.40% | 6.62 | |
| 30 Sep 2022 | 1.38% | 5.95 | |
| 14 Oct 2022 | 1.35% | 5.39 | |
| 31 Oct 2022 | 1.40% | 4.78 | |
| 15 Nov 2022 | 1.31% | 4.30 | 10-Q filed |
| 30 Nov 2022 | 1.49% | 6.23 | |
| 15 Dec 2022 | 1.31% | 4.45 | |
| 30 Dec 2022 | 1.39% | 1.00 |
See also: Oragenics Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.